This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.
The collaboration and licence agreement will see Biogen and Sage jointly develop and commercialise zuranolone, an investigational treatment for major depressive disorder (MDD), postpartum depression and other psychiatric disorders. ... Major depressive
study for major depressive disorder (MDD), despite showing promise in an earlier, smaller trial. ... We observed a consistent improvement of depressive symptoms over time with Nuplazid but, unfortunately, the robust positive results from our CLARITY-1
Eleusis’ trial comes after the non-profit Usona Institute launched a phase 2 trial of psilocybin – found in ‘magic mushrooms’ – as a treatment for major depressive disorder.
The company has just revealed that the pivotal phase 3 MOUNTAIN trial of its drug SAGE-217 – also known as zuranolone – missed its primary endpoint in major depressive disorder (MDD), wiping
treatment for psychotic symptoms in other diseases, including schizophrenia, dementia and major depressive disorder.
SUD). It then followed this up with the approval in December 2018, of reSET-O, for the treatment of Opioid Use Disorder, which it co-markets with Novartis subsidiary Sandoz.. ... to develop a similar CBT-based app for the treatment of major depressive
More from news
Approximately 8 fully matching, plus 57 partially matching documents found.
condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.
74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...